M.L. Rothenberg

917 total citations
14 papers, 781 citations indexed

About

M.L. Rothenberg is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, M.L. Rothenberg has authored 14 papers receiving a total of 781 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Reproductive Medicine. Recurrent topics in M.L. Rothenberg's work include Cancer Treatment and Pharmacology (6 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer therapeutics and mechanisms (4 papers). M.L. Rothenberg is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer therapeutics and mechanisms (4 papers). M.L. Rothenberg collaborates with scholars based in United States and Israel. M.L. Rothenberg's co-authors include Elise C. Kohn, Seth M. Steinberg, Maria J. Merino, Helen C. Hollingsworth, E Reed, Debra O. Adamo, Gisele Sarosy, J Jacob, Robert E. Cunnion and Frederick P. Ognibene and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Oncology.

In The Last Decade

M.L. Rothenberg

14 papers receiving 752 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M.L. Rothenberg United States	9	368	363	214	127	126	14	781
A Harłozińska Poland	14	234 0.6×	219 0.6×	144 0.7×	76 0.6×	67 0.5×	55	587
Joan Sorich United States	13	330 0.9×	439 1.2×	251 1.2×	63 0.5×	97 0.8×	31	759
Angela Thornton United States	9	322 0.9×	275 0.8×	153 0.7×	102 0.8×	66 0.5×	10	707
Corrine Zarwan United States	13	321 0.9×	691 1.9×	203 0.9×	214 1.7×	200 1.6×	27	1.1k
Volker Moebus Germany	15	164 0.4×	393 1.1×	144 0.7×	224 1.8×	97 0.8×	52	705
Saverio Danese Italy	16	228 0.6×	408 1.1×	266 1.2×	199 1.6×	114 0.9×	31	880
Amanda Gordon United States	7	191 0.5×	314 0.9×	400 1.9×	81 0.6×	107 0.8×	15	801
Eleni Timotheadou Greece	17	303 0.8×	616 1.7×	95 0.4×	201 1.6×	222 1.8×	76	1.0k
Encarna Adrover Spain	14	297 0.8×	864 2.4×	87 0.4×	366 2.9×	177 1.4×	40	1.1k
M. R. Sertoli Italy	11	141 0.4×	391 1.1×	87 0.4×	82 0.6×	67 0.5×	26	638

Countries citing papers authored by M.L. Rothenberg

Since Specialization

Citations

This map shows the geographic impact of M.L. Rothenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.L. Rothenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.L. Rothenberg more than expected).

Fields of papers citing papers by M.L. Rothenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.L. Rothenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.L. Rothenberg. The network helps show where M.L. Rothenberg may publish in the future.

Co-authorship network of co-authors of M.L. Rothenberg

This figure shows the co-authorship network connecting the top 25 collaborators of M.L. Rothenberg. A scholar is included among the top collaborators of M.L. Rothenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.L. Rothenberg. M.L. Rothenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Jones, Suzanne F., William C. Zamboni, H. A. Burris, et al.. (2009). Phase I and pharmacokinetic (PK) study of IHL-305 (pegylated liposomal irinotecan) in patients with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 2547–2547. 5 indexed citations

Rothenberg, M.L., Matilde Navarro, Charles Butts, et al.. (2007). 3012 ORAL Capecitabine + oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results. European Journal of Cancer Supplements. 5(4). 238–239. 2 indexed citations

Calcutt, M. Wade, et al.. (2006). 297 POSTER Phase I and pharmacokinetic trial of SJG-136 administered on a daily × 5 schedule. European Journal of Cancer Supplements. 4(12). 93–93. 1 indexed citations

Haller, Daniel G., Jim Cassidy, Stephen Clarke, et al.. (2006). Tolerability of fluoropyrimidines appears to differ by region. Journal of Clinical Oncology. 24(18_suppl). 3514–3514. 27 indexed citations

Syed, S., et al.. (2004). 599 Phase I and pharmacokinetic (PK) study of OSI-7904L in combination with Cisplatin (CDDP) in patients with advanced solid tumors. European Journal of Cancer Supplements. 2(8). 181–181. 3 indexed citations

Shapiro, Jeremy, M.L. Rothenberg, Gisele Sarosy, et al.. (1998). Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Cancer. 83(9). 1980–1988. 17 indexed citations

Gazitt, Yair, et al.. (1998). Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.. International Journal of Oncology. 13(4). 839–48. 67 indexed citations

Hollingsworth, Helen C., Elise C. Kohn, Seth M. Steinberg, M.L. Rothenberg, & Maria J. Merino. (1995). Tumor angiogenesis in advanced stage ovarian carcinoma.. PubMed. 147(1). 33–41. 339 indexed citations

Reed, E, John E. Janik, M. A. Bookman, et al.. (1993). High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.. Journal of Clinical Oncology. 11(11). 2118–2126. 18 indexed citations

10.

Sarosy, Gisele, Elise C. Kohn, David A. Stone, et al.. (1992). Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.. Journal of Clinical Oncology. 10(7). 1165–1170. 163 indexed citations

11.

Rothenberg, M.L., Robert F. Ozols, Eli Glatstein, et al.. (1992). Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.. Journal of Clinical Oncology. 10(5). 727–734. 22 indexed citations

12.

Burris, H.A., M.L. Rothenberg, John G. Kuhn, & Daniel D. Von Hoff. (1992). Clinical trials with the topoisomerase I inhibitors.. PubMed. 19(6). 663–9. 55 indexed citations

13.

O’Shaughnessy, J., R. Wittes, Gerard Burke, et al.. (1991). Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials.. Journal of Clinical Oncology. 9(12). 2225–2232. 60 indexed citations

14.

Shoenfeld, Yehuda, M.L. Rothenberg, Shlomo Berliner, et al.. (1982). Absence of Predictive Parameters for CNS Involvement in Adult non‐Lymphocytic Leukaemia at Time of Diagnosis. Scandinavian Journal of Haematology. 28(4). 335–340. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact